Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
April 22 2024 - 4:30PM
Business Wire
Preclinical findings showed robust anti-tumor
activity of ADI-270 in multiple CD70-positive solid and
hematological cancer models
ADI-270 demonstrated enhanced functional
potency and resilience in tumor microenvironment
On track to file an investigational new drug
(IND) application for ADI-270 in 2Q 2024
Preclinical data will be featured in oral
presentation on May 10, 2024
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing allogeneic gamma delta T cell
therapies for autoimmune diseases and cancer, today announced that
an abstract featuring new preclinical data highlighting ADI-270, an
armored allogeneic “off-the-shelf” gamma delta CAR (chimeric
antigen receptor) T cell therapy candidate targeting CD70 positive
cancers, has been selected for an oral presentation at the ASGCT
27th Annual Meeting taking place from May 7-11, 2024, in Baltimore,
MD. The oral presentation will take place on May 10, 2024 in the
Targeted Gene and Cell Therapy session, co-chaired by Adicet Bio’s
Chief Scientific Officer, Blake Aftab, Ph.D.
“We look forward to sharing new preclinical data at ASGCT
further illustrating ADI-270’s robust anti-tumor activity with a
differentiated method for targeting CD70 across multiple solid and
hematologic cancers,” said Blake Aftab, Ph.D., Chief Scientific
Officer of Adicet Bio. “ADI-270 is a next-generation CAR T cell
therapy candidate designed to capitalize on potent tumor
infiltration associated with the gamma delta T cell platform.
ADI-270 is further enhanced with armoring to address suppressive
tumor microenvironments and to address clearance by host T cells.
In preclinical studies, ADI-270 demonstrated enhanced functional
persistence and potency, including unique contribution of innate
anti-tumor immunity, compared to multiple clinically relevant
benchmarks in cancers expressing CD70. Supported by these
encouraging data, we look forward to advancing ADI-270’s clinical
development and remain on track to file an IND in renal cell
carcinoma this quarter.”
Findings from this study have further characterized and have
provided comparative benchmarking for the mechanisms by which
ADI-270 provides enhanced functionality and potency in CD70
positive expressing tumors such as clear cell renal cell carcinoma
(ccRCC) and facilitates a robust anti-tumor effect that supports
its continued development. The preclinical findings indicate:
- ADI-270 demonstrated potent in vitro cytotoxicity against
multiple CD70 positive tumor cell lines expressing varying levels
of CD70.
- ADI-270 demonstrated robust cytotoxicity against heterogeneous
CD70 negative and CD70 positive tumor cell cultures, highlighting
the potential of gamma delta CAR T cells to be effective against
tumors with mixed antigen expression.
- ADI-270’s unique use of CD27-based targeting of CD70
demonstrated robust CAR-mediated killing in multiple cancer models
including ccRCC, non-small cell lung cancer and T cell lymphoma,
and including those models with lower levels of CD70
expression.
- ADI-270 inhibited tumor growth in the context of suppressive
tumor microenvironment attributed to inclusion of dominant-negative
transforming growth factor beta receptor and demonstrated
resilience to clearance by host T cells attributed to the function
of CD27-based CAR targeting of CD70 also expressed on host T
cells.
- Robust anti-tumor effects in an in vivo model of ccRCC, such as
tumor infiltration, proliferation, and effector function, were
observed after administration, resulting in eradication of CD70
positive tumor cells.
Details for the oral presentation are as follows:
Title: ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T
cell Therapy Designed for Multiple Solid and Hematological Cancer
Indications Oral Session: Targeted Gene and Cell Therapy
Session I Presenting Author: Shon Green, Ph.D. Date &
Time: May 10, 2024 at 5:00 PM EST
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for autoimmune diseases and cancer. Adicet is advancing a pipeline
of “off-the-shelf” gamma delta T cells, engineered with chimeric
antigen receptors (CARs), to facilitate durable activity in
patients. For more information, please visit our website at
https://www.adicetbio.com.
Forward-Looking Statements
This press release contains "forward-looking statements" of
Adicet within the meaning of the Private Securities Litigation
Reform Act of 1995 relating to the business and operations of
Adicet. The words “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “target,” “would” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements include, but
are not limited to, express or implied statements regarding:
preclinical and clinical development of Adicet’s product
candidates, including future plans or expectations for ADI-270, its
unique use of CD27-based targeting of CD70 and the potential
potency, safety, durability, tolerability and efficacy of the
product candidate; the Company’s expectations regarding regulatory
filings and clearances, including the submission of an IND for
ADI-270 in renal cell carcinoma in the second quarter of 2024; and
the Company’s expectations regarding ADI-270’s potential to be
effective in other indications, such as tumors with mixed antigen
expression.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs of future events,
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those
set forth in or implied by such forward-looking statements,
including without limitation, the effect of global economic
conditions and public health emergencies on Adicet’s business and
financial results, including with respect to disruptions to our
preclinical and clinical studies, business operations, employee
hiring and retention, and ability to raise additional capital;
Adicet’s ability to execute on its strategy including obtaining the
requisite regulatory approvals on the expected timeline, if at all;
that positive results, including interim results, from a
preclinical or clinical study may not necessarily be predictive of
the results of future or ongoing studies; clinical studies may fail
to demonstrate adequate safety and efficacy of Adicet’s product
candidates, which would prevent, delay, or limit the scope of
regulatory approval and commercialization; and regulatory approval
processes of the U.S. Food and Drug Administration and comparable
foreign regulatory authorities are lengthy, time-consuming, and
inherently unpredictable; and Adicet’s ability to meet production
and product release expectations. For a discussion of these and
other risks and uncertainties, and other important factors, any of
which could cause Adicet’s actual results to differ from those
contained in the forward-looking statements, see the section
entitled “Risk Factors” in Adicet’s most recent annual report on
Form 10-K and our periodic reports on Form 10-Q and Form 8-K filed
with the U.S. Securities and Exchange Commission (SEC), as well as
discussions of potential risks, uncertainties, and other important
factors in Adicet’s other filings with the SEC. All information in
this press release is as of the date of the release, and Adicet
undertakes no duty to update this information unless required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240422828682/en/
Adicet Bio, Inc. Investor and Media Contacts
Anne Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200
janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Jul 2024 to Aug 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Aug 2023 to Aug 2024